Exhibit 99.1
FOR IMMEDIATE RELEASE
Contact: | Adam C. Derbyshire | Mike Freeman | ||
Senior Vice President and | Director, Investor Relations and | |||
Chief Financial Officer | Corporate Communications | |||
919-862-1000 | 919-862-1000 |
SALIX PHARMACEUTICALS TO PRESENT AT ROTH
CAPITAL PARTNERS GROWTH STOCK CONFERENCE
RALEIGH, NC, February 11, 2004 - Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that the Company will present at the Roth Capital Partners 16th Annual Growth Stock Conference in Dana Point, CA on Wednesday, February 18 at 12:00 noon ET.
Interested parties can access a live audio web cast of the presentation athttp://www.salix.com. A replay of the presentation will be available beginning at 3:00 p.m. ET, Wednesday, February 18 and will be available through Tuesday, February 24.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company’s 100-member gastroenterology specialty sales and marketing team. Salix trades on the Nasdaq National Market under the ticker symbol “SLXP.”
For more information please contact the Company at 919-862-1000 or visit our web site atwww.salix.com. Information on our web site is not incorporated in our SEC filings.